Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences   

Rhea-AI Summary

Catabasis Pharmaceuticals (NASDAQ:CATB) announces CEO Jill C. Milne will present a corporate overview and details about their lead program, QLS-215, at upcoming virtual investor conferences. The H.C. Wainwright Global Life Sciences Conference will take place on March 9-10, 2021, with presentations available on-demand. Milne will also present at the Oppenheimer 31st Annual Healthcare Conference on March 18, 2021, at 10:00am ET. Additionally, Catabasis will participate in the Guggenheim Healthcare Talks on April 1, 2021. Webcasts for these events can be accessed via their website.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, plans to present a corporate overview and provide information about our lead program QLS-215, in preclinical development for the treatment of hereditary angioedema, at the following virtual investor conferences this month:

• H.C. Wainwright Global Life Sciences Conference. Presentations will be available on-demand from March 9-10, 2021.
• Oppenheimer 31^st Annual Healthcare Conference on Thursday, March 18, 2021 at 10:00am ET.

Webcasts of the events can be accessed from the investors section of www.catabasis.com. Archived replays will be available for 30 days following the event.

Catabasis is also participating in Guggenheim Healthcare Talks, 2021 Genomic Medicines & Rare Disease, on April 1, 2021.

About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope with life-changing therapies to patients and families affected by rare diseases. Our lead program, QLS-215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005131/en/

FAQ

What is QLS-215 and its significance for Catabasis Pharmaceuticals?

QLS-215 is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development aimed at treating hereditary angioedema.

When will Catabasis Pharmaceuticals present at the H.C. Wainwright Global Life Sciences Conference?

Catabasis Pharmaceuticals will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021, with presentations available on-demand.

What date and time is the Oppenheimer Healthcare Conference presentation by Catabasis?

The Oppenheimer 31st Annual Healthcare Conference presentation by Catabasis Pharmaceuticals is scheduled for March 18, 2021, at 10:00am ET.

How can I access the webcasts of Catabasis Pharmaceuticals' presentations?

Webcasts of Catabasis Pharmaceuticals' presentations can be accessed from the investors section of their website at www.catabasis.com.

What other events is Catabasis Pharmaceuticals participating in during March 2021?

In addition to the H.C. Wainwright and Oppenheimer conferences, Catabasis is participating in Guggenheim Healthcare Talks on April 1, 2021.